Suppr超能文献

米索前列醇预防和治疗产后出血:我们了解什么?下一步是什么?

Misoprostol for prevention and treatment of postpartum hemorrhage: what do we know? What is next?

机构信息

Gynuity Health Projects, New York, NY 10010, USA.

出版信息

Int J Gynaecol Obstet. 2012 Oct;119 Suppl 1:S35-8. doi: 10.1016/j.ijgo.2012.03.013. Epub 2012 Aug 9.

Abstract

Misoprostol is an effective and safe uterotonic for the prevention and treatment of postpartum hemorrhage (PPH). A 600-μg oral dose of misoprostol has been shown to prevent PPH in community-based randomized controlled trials. An 800-μg sublingual dose of misoprostol appears to be a good first-line treatment for controlling PPH. Adverse effects after use of misoprostol for PPH prevention or treatment may include shivering and fever. These effects are transient, resolve on their own, and are not life threatening. Misoprostol can play an important role in settings with limited access to oxytocin, and where there is no other option for PPH care.

摘要

米索前列醇是一种预防和治疗产后出血(PPH)的有效且安全的子宫收缩剂。社区随机对照试验表明,600μg 口服剂量的米索前列醇可预防 PPH。800μg 舌下含服米索前列醇似乎是控制 PPH 的一线治疗方法。米索前列醇用于预防或治疗 PPH 后的不良反应可能包括寒战和发热。这些作用是短暂的,会自行消退,且不会危及生命。在催产素获取有限的环境中,以及在没有其他 PPH 治疗选择的情况下,米索前列醇可以发挥重要作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验